newsfilter
← Interviews
Goldman Sachs31 min

Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine

Dave Ricks, John Waldron

Fireside Chat, Interview

Eli Lilly CEO Dave Ricks outlines a strategic pivot from the current GLP-1 obesity drug boom to a 2030s focus on brain health and gene therapy, backed by a plan to double R&D spending to $11 billion annually. The company is accelerating development cycles by 50% through a global "follow the sun" manufacturing model and investing heavily in AI-driven discovery to overcome traditional productivity curves, while simultaneously scaling production capacity tenfold to meet demand. To secure future growth, Lilly is shifting toward talent-focused acquisitions and diversifying intellectual property protections against regulatory and political headwinds as it targets the treatment of neurodegenerative diseases and chronic conditions.